Lorazepam BP / EP / IP / USP

Global calcium is one of the leading manufacturers and exporters of lorazepam CAS no. 846-49-1, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, global calcium has stood the test of time since its inception in 1979.

As manufacturer of lorazepam we hereby state the following facts about the drug:

Lorazepam is a benzodiazepine with anxiolytic, anti-anxiety, anticonvulsant, anti-emetic, and sedative properties. Lorazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) on the GABA receptors by binding to a site that is distinct from the GABA binding site in the central nervous system. This leads to an increase in chloride channel opening events, facilitation of chloride ion conductance, membrane hyperpolarization, and eventually inhibition of the transmission of nerve signals, thereby decreasing nervous excitation

Therapeutic uses and effectiveness:

• Lorazepam is FDA approved for short-term (4 months) relief of anxiety symptoms related to anxiety disorders, anxiety-associated insomnia, anesthesia premedication in adults to relieve anxiety, or to produce sedation/amnesia, and treatment of status epilepticus
• Anti-anxiety agents: Agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting the clarity of consciousness or neurologic conditions
• Antiemetics: Drugs used to prevent nausea or vomiting
• Hypnotics and sedatives: Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety
• Anticonvulsants: Drugs used to prevent seizures or reduce their severity
• GABA modulators: Substances that do not act as agonists or antagonists but do affect the GABA receptor-ionophore complex
• Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia

Other related information:

• As with most benzodiazepines, lorazepam therapy has not been associated with serum aminotransferase or alkaline phosphatase elevations, and clinically apparent liver injury from lorazepam has not been reported and must be very rare if it occurs at all
• Lorazepam is a DEA schedule IV controlled substance. Substances in the DEA schedule IV have a low potential for abuse relative to substances in schedule III
• Like most benzodiazepines, adverse reactions to lorazepam include CNS and respiratory depression, which are dose-dependent. More severe effects occur with high doses

Global calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market